1. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials 
The Lancet Diabetes & Endocrinology 
Volume 4, Issue 10, Pages (October 2016)
DOI: /S (16)
Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

2. Figure 1
Effects on major vascular events per mmol/L reduction in LDL cholesterol, by baseline renal function
Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular filtration rate. RR=rate ratio.
The Lancet Diabetes & Endocrinology 2016 4, DOI: ( /S (16) )
Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

3. Figure 2
Effects on major coronary events per mmol/L reduction in LDL cholesterol, by baseline renal function
Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular filtration rate. RR=rate ratio.
The Lancet Diabetes & Endocrinology 2016 4, DOI: ( /S (16) )
Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions

4. Figure 3
Effects on cause-specific mortality per mmol/L reduction in LDL cholesterol, by baseline renal function
Data for participants with missing creatinine values at baseline are included in totals. Black squares and horizontal lines represent 99% CIs. White diamonds represent 95% CIs. Vertical dotted line represents overall RR for each outcome. eGFR=estimated glomerular filtration rate. RR=rate ratio.*Includes 583 deaths from an unknown cause in the statin or more intensive regimen group and 653 deaths from an unknown cause in the control or less intensive regimen group.
The Lancet Diabetes & Endocrinology 2016 4, DOI: ( /S (16) )
Copyright © 2016 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Terms and Conditions